ASF1A knockdown reduced H3K56ac in vivo by a xenograft tumor model, suggesting that ASF1A enhanced the development of CML via H3K56ac in vivo (Fig. 7a, b). Here, ASF1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.